Bacterial colonization, probiotics, and clinical disease

Journal of Pediatrics

Volumn 149, Issue 5 SUPPL., 2006, Pages

  Weng, Meiqian ^a   Walker, W Allan ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; NUCLEOTIDE BINDING PROTEIN; PROBIOTIC AGENT; TOLL LIKE RECEPTOR;

ARTICLE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIUM ADHERENCE; BACTERIUM CONTAMINATION; CD4 LYMPHOCYTE COUNT; DIET SUPPLEMENTATION; DNA MICROARRAY; ENTERITIS; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IMMUNE MEDIATED INJURY; INFECTION RISK; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; LACTOBACILLUS; MUCOSAL IMMUNITY; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; REGULATORY T LYMPHOCYTE; RISK FACTOR;

EID: 33747789129     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.06.061     Document Type: Article

References (82)

1. Bach J.F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347 (2002) 911-920
2. Aberg N., Hesselmar B., Aberg B., and Eriksson B. Increase of asthma, allergic rhinitis and eczema in Swedish schoolchildren between 1979 and 1991. Clin Exp Allergy 25 (1995) 815-819
3. Holt P.G., and Macaubas C. Development of long-term tolerance versus sensitization to environmental allergens during the perinatal period. Curr Opin Immunol 9 (1997) 782-787
4. Stene L.C., and Nafstad P. Relation between occurrence of type 1 diabetes and asthma. Lancet 357 (2001) 607-608
5. Yazdanbakhsh M., Kremsner P.G., and Ree R.V. Allergy, parasites, and the hygiene hypothesis. Science 296 (2002) 490-494
6. Romagnani S. The increased prevalence of allergy and the hygiene hypothesis. missing immune deviation, reduced immune suppression, or both?. Immunology 112 (2004) 352-363
7. Holt P.G. Parasites, atopy, and the hygiene hypothesis. resolution of a paradox?. Lancet 356 (2000) 1699-1701
8. Shi H.N., and Walker A. Bacterial colonization and the development of intestinal defences. Can J Gastroenterol 18 (2004) 493-500
9. Macpherson A.J., and Uhr T. Compartmentalization of the mucosal immune response to commensal intestinal bacteria. Ann N Y Acad Sci 1029 (2004) 36-43
10. Yamanaka T., Helgeland L., Farstad I.N., Fukushinma H., Midtvedt T., and Braandtzaeg P. Microbial colonization drives lymphocyte accumulation and differentiation in the follicle-associated epithelium of Peyer's patches. J Immunol 170 (2003) 816-822
11. Schofield D.A., Westwater C., and Balish E. Beta-defensin expression in immunocompetent and immunodeficient germ-free and Candida albicans-monoassociated mice. J Infect Dis 190 (2004) 1327-1334
12. Hooper L.V., Wong M.H., Thelin A., Hansson L., Falk P.G., and Gordon J.L. Molecular analysis of commensal host-microbial relationships in the intestine. Science 291 (2001) 881-884
13. Umesaki Y., and Setoyama H. Structure of the intestinal flora responsible for development of the gut immune system in a rodent model. Microbes Infect 2 (2000) 1343-1351
14. Macpherson A.J., and Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 303 (2004) 1624-1625
15. Ibnou-Zekri N., Blum S., Schiffrin E.J., and Von der Weid T. Divergent patterns of colonization and immune response elicited from two intestinal lactobacillus strains that display similar properties in vitro. Infect Immunol 71 (2003) 428-436
16. Rhee K.J., Sethupathi P., Driks A., Lanning D.K., and Knight K.L. Role of commensal bacteria in development of gut-associated lymphoid tissues and preimmune antibody repertoire. J Immunol 172 (2004) 1118-1124
17. Prioult G., Fliss I., and Pecquet S. Effect of probiotic bacteria on induction and maintenance of oral tolerance to β-lactoglobulin in gnotobiotic mice. Clin Diagn Lab Immunol 10 (2003) 787-792
18. He F., Ouwehand A.C., Isolauri E., Hashimoto H., Benno Y., and Salminen S. Comparison of mucosal adhesion and species identification of bifidobacteria isolated from healthy and allergic infants. FEMS Immunol Med Microbiol 30 (2001) 43-47
19. Linskens R.K., Huijsdens X.W., Savelkoul P.H.M., Vandenbroucke-Grauls C.M.J.E., and Meuwissen S.G.M. The bacterial flora in inflammatory bowel disease. current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol 234 (2001) 29-40
20. Friman V., Nowrouzian F., Adlerberth I., and Wold A.E. Increased frequency of intestinal Escherichia coli-carrying genes for S fimbriae and haemolysin in IgA-deficient individuals. Microb Pathog 32 (2002) 35-42
21. Aim J.S., Swartz J., Bjorksten B., Engstrand L., Engstrom J., Kuhn I., et al. An anthroposophic lifestyle and intestinal microflora in infancy. Pediatr Allergy Immunol 13 (2002) 402-411
22. Samuelsson U., and Ludvigsson J. The concentrations of short-chain fatty acids and other microflora-associated characteristics in faeces from children with newly diagnosed type 1 diabetes and control children and their family members. Diabetes Med 21 (2004) 64-67
23. Walker A. Role of nutrients and bacterial colonization in the development of intestinal host defense. J Pediatr Gastroenterol Nutr 30 Suppl 2 (2000) S2-S7
24. Bourlioux P., Koletzko B., Guarner F., and Braesco V. The intestine and its microflora are partners for the protection of the host. report on the Danone Symposium on "The Intelligent Intestine," Paris, June 14, 2002. Am J Clin Nutr 78 (2003) 675-683
25. Field C.J. The immunological components of human milk and their effect on immune development in infants. J Nutr 135 (2005) 1-4
26. Hanson L.A., Korotkova M., and Telemo E. Breast-feeding, infant formulas, and the immune system. Ann Allegy Asthma Immunol 90 Suppl 3 (2003) 59-63
27. Neikkilä M.P., and Saris P.E.J. Inhibition of Staphylococcus aureus by the commensal bacteria of human milk. J Appl Microbiol 95 (2003) 471-478
28. Bomba A., Nemcova R., Gancarcikova S., Herich R., Pistl J., Revajova V., et al. The influence of omega-3 polyunsaturated fatty acids (omega-3 PUFAs) on lactobacilli adhesion to the intestinal mucosa and on immunity in gnotobiotic piglets. Berl Munch Tierarztl Wochenschr 116 (2003) 312-316
29. Bry L., Falk P.G., Midtvedt T., and Gordon J.I. A model of host-microbial interactions in an open mammalian ecosystem. Science 273 (1996) 1380-1383
30. Coyne M.J., Reinap B., Lee M.M., and Comstock L.E. Human symbionts use a host-like pathway for surface fucosylation. Science 307 (2005) 1778-1781
31. Gebbink M.F., Claessen D., Bouma B., Dijkhuizen L., and Wösten H.A. Amyloids. a functional coat for microorganisms. Nat Rev Microbiol 3 (2005) 333-341
32. Takeda K., Kaisho T., and Akira S. Toll-like receptors. Annu Rev Immunol 21 (2003) 335-376
33. Zhang D., Zhang G., Hayden M.S., Greenblatt M.B., Bussey C., Flavel R.A., et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 303 (2004) 1522-1526
34. Underhill D.M. Toll-like receptors and microbes take aim at each other. Curr Opin Immunol 16 (2004) 483-487
35. Cook D.N., Pisetsky D.S., and Schwartz D.A. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 5 (2004) 975-979
36. Abreu M.T., Fukata M., and Arditi M. TLR signaling in the gut in health and disease. J Immunol 174 (2005) 4453-4460
37. Kelly D., and Conway S. Bacterial modulation of mucosal innate immunity. Mol Immunol 42 (2005) 895-901
38. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., Edberg S., and Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118 (2004) 229-241
39. Caramalho I., Lopes-Carvalho T., Ostler D., Zelenay S., Haury M., and Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 197 (2004) 403-411
40. Vora P., Youdim A., Thomas L.S., Fukata M., Tesfay S.Y., Lukasek K., et al. β-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol 173 (2004) 5398-5405
41. Eder W., Kimecki W., Yu L., von Mutius E., Riedler J., Braun-Fahrlander C., et al. Toll-like receptor 2 as a major gene for asthma in children of European farmers. J Allergy Clin Immunol 113 (2004) 482-488
42. Park Y., Park S., Yoo E., Kim D., and Shin H. Association of the polymorphism for toll-like receptor 2 with type 1 diabetes susceptibility. Ann N Y Acad Sci 1037 (2004) 170-174
43. Franchimont D., Vermeire S., EI Housni H., Pierik M., Van Steen K., Gustot T., et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 53 (2004) 987-992
44. Ogus A.C., Yoldas B., Ozdemir T., Uguz A., Olcen S., Keser I., et al. The Arg753Gln polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. Eur Respir J 23 (2004) 219-223
45. Hawn T.R., Verbon A., Lettinga K.D., Zhao L.P., Li S.S., Laws R.J., et al. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to Legionnaires' disease. J Exp Med 198 (2003) 1563-1572
46. Noguchi E., Nishimura F., Fukai H., Kim J., Ichikawa K., Shibasaki M., et al. An association study of asthma and total serum immunoglobin E levels for toll-like receptor polymorphisms in a Japanese population. Clin Exp Allergy 34 (2004) 163-166
47. Uehara A., Yang S., Fujimoto Y., Fukase K., Kusumoto S., Shibata K., et al. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell Microbiol 7 (2005) 53-61
48. Netea M.G., Ferwerda G., de Jong D.J., Jansen T., Jacobs L., Kramer M., et al. Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol 174 (2005) 6518-6523
49. van Heel D.A., Ghosh S., Butler M., Hunt K.A., Lundberg A.M., Ahmad T., et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet 365 (2005) 1794-1796
50. Buning C., Molnar T., Nagy F., Lonovics J., Weltrich R., Bochow B., et al. NOD2/CARD15 gene polymorphism in patients with inflammatory bowel disease. is Hungary different?. World J Gastroenterol 11 (2005) 407-411
51. Gazouli M., Mantzaris G., Kotsinas A., Zacharatos P., Papalambros E., Archimandritis A., et al. Association between polymorphism in the toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J Gastroenterol 11 (2005) 681-685
52. Zouiten-Mekki L., Zaouali H., Boubaker J., Karoui S., Fekih M., Matri S., et al. CARD15/NOD2 in a Tunisian population with Crohn's disease. Dig Dis Sci 50 (2005) 130-135
53. Gao M., Cao Q., Luo L.H., Wu M.L., Hu W.L., and Si J.M. NOD2/CARD15 gene polymorphism and susceptibility to Crohn's disease in Chinese Han population. Zhonghua Nei Ke Za Zhi 44 (2005) 210-212
54. Idestrom M., Rubio C., Granath F., Finkel Y., and Hugot J.P. CARD15 mutations are rare in Swedish pediatric Crohn disease. J Pediatr Gastroenterol Nutr 40 (2005) 456-460
55. McGovern D.P., Hysi P., Ahmad T., van Heel D.A., Moffatt M.F., Carey A., et al. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet 14 (2005) 1245-1250
56. Otte J.M., Cario E., and Podolsky D.K. Mechanism of cross-hyporesponsiveness to toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology 126 (2004) 1054-1070
57. Kim J.G., Lee S.J., and Kagnoff M.F. NOD1 is an essential signal transducer in intestinal epithelial cells infected with bacteria that avoid recognition by toll-like receptors. Infect Immunol 72 (2004) 1487-1495
58. Melmed G., Thomas L.S., Lee N., Tesfay S.Y., Lukasek K., Michelsen K.S., et al. Human intestinal epithelial cells are broadly unresponsive to toll-like receptor 2-dependent bacterial ligands. implications for host-microbial interactions in the gut. J Immunol 170 (2003) 1406-1415
59. Hornef M.W., Frisan T., Vandewalle A., Normark S., and Richter-Dahlfors A. toll-like receptor 4 resides in the Golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells. J Exp Med 195 (2002) 559-570
60. Hornef M.W., Normark B.H., Vandewalle A., and Normark S. Intracellular recognition of lipopolysaccharide by toll-like receptor 4 in intestinal epithelial cells. J Exp Med 198 (2003) 1225-1235
61. Fukao T., and Koyasu S. PI3K and negative regulation of TLR signaling. Trends Immunol 24 (2003) 358-363
62. Wald D., Qin J., Zhao Z., Qian Y., Naramura M., Tian L., et al. SIGIRR, a negative regulator of toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 4 (2003) 920-927
63. Janssens S., Burns K., Tschopp J., and Beyaert R. Regulation of interleukin-1 and lipopolysaccharide-induced NF-κB activation by alternative splicing of MyD88. Curr Biol 12 (2002) 467-471
64. Kobayashi K., Hernandez L.D., and Galan J.E. IRAK-M is a negative regulator of toll-like receptor signaling. Cell 110 (2002) 191-202
65. Yamakami M., and Yokosawa H. Tom1 (target of Myb 1) is a novel negative regulator of interleukin-1- and tumor necrosis factor-induced signaling pathways. Biol Pharm Bull 27 (2004) 564-566
66. Kinjyo I., Hanada T., Inagaki-Ohara K., Mori H., Aki D., Ohishi M., et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 17 (2002) 583-591
67. Watanabe T., Kitani A., Murray P., and Strober W. NOD2 is a negative regulator of toll-like receptor 2-mediated T helper type 1 responses. Nature 5 (2004) 800-808
68. Shinohara H., Inoue A., Toyama-Sorimachi N., Nagai Y., Yasuda T., Suzuki H., et al. DOK-1 and DOK-2 are negative regulation of lipopolysaccharide-induced signaling. J Exp Med 201 (2005) 333-339
69. Chuang T.H., and Ulevitch R. Triad3A, an E3 ubiquitin-protein ligase regulating toll-like receptors. Nat Immunol 5 (2004) 495-502
70. Gon Y., Asai Y., Hashimoto S., Mizumura K., Jibiki I., Machino T., et al. A20 inhibits toll-like receptor 2- and 4-mediated interleukin 8 synthesis in airway epithelial cells. Am J Respir Cell Mol Biol 31 (2004) 330-336
71. Brint E.K., Xu D.M., Liu H.Y., Dunne A., Mckenzie A.N., O'Neill L.A., et al. ST2 is an inhibitor of interleukin 1 receptor and toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 5 (2004) 373-379
72. Divanovic S., Trompette A., Atabani S.F., Madan R., Golenbock D.T., Visintin A., et al. Negative regulation of toll-like receptor 4 signaling by the toll-like receptor homolog RP105. Nat Immunol 6 (2005) 571-578
73. Hamerman J.A., Tchal N.K., Lowell C.A., and Lanier L.L. Enhanced toll-like receptor responses in the absence of signaling adaptor DAP12. Nat Immunol 6 (2005) 579-586
74. Rimoldi M., Chieppa M., Vulcano M., Allavena P., and Rescigno M. Intestinal epithelial cells control dendritic cell function. Ann N Y Acad Sci 1029 (2004) 66-74
75. Sansonetti P. Phagocytosis of bacterial pathogens. implications in the host response. Semin Immunol 13 (2001) 381-390
76. Shroff K.E., Meslin K., and Cebra J.J. Commensal enteric bacteria engender a self-limiting humoral mucosal immune response while permanently colonizing the gut. Infect Immunol 63 (1995) 3904-3913
77. Iimura M., Gallo R.L., Hase K., Miyamoto Y., Eckmann L., and Kagnoff M.F. Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens. J Immunol 174 (2005) 4901-4907
78. Neish A.S., Gewirtz A.T., Zeng H., Young A.N., Hobert M.E., Karmali V., et al. Prokaryotic regulation of epithelial responses by inhibition of IκB-α ubiquitination. Science 289 (2000) 1560-1563
79. Fort M.M., Mozaffarian A., Stover A.G., Correia Jda S., Johnson D.A., Crane R.T., et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol 174 (2005) 6416-6423
80. Rook G.A., and Brunet L.R. Microbes, immunoregulation, and the gut. Gut 54 (2005) 317-320
81. Kalliomaki M., Salminen S., Poussa T., Arvilommi H., and Isolauri E. Probiotics and prevention of atopic disease. 4-year follow-up of a randomized placebo-controlled trial. Lancet 361 (2003) 1869-1871
82. Sullivan A., and Nord C.E. Probiotics and gastrointestinal disease. J Intern Med 257 (2005) 78-92